Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Inclusion Criteria:

• ≥18 years of age

• Biopsy proven fibrillary glomerulonephritis

• Proteinuria > 1.0 g/24hrs prior to initiation of immunosuppressive therapy

• eGFR ≥ 20 ml/min/BSA

Exclusion Criteria:

• Secondary FGN (due to monoclonal gammopathy, autoimmune disease or malignancy)

• Presence of a secondary pathology on biopsy (e.g. diabetic nephropathy)

• Hepatitis B, C or HIV positive

• Pregnant or breast-feeding

• Active infection

• Kidney transplant

• Anemia with Hgb < 8.0 g/dL

• Thrombocytopenia with platelet count < 100'000

• Any other disease, metabolic dysfunction, physical examination finding, or clinicallaboratory finding giving reasonable suspicion of a disease or condition thatcontraindicates the use of an investigational drug or that may affect theinterpretation of the results or render the patient at high risk from treatmentcomplication

• Patients who have received cyclophosphamide in the last 6 months

• Patients who have received ACTH and/or mycophenolate mofetil in the last 30 days

• Patient who are on prednisone therapy at a dose > 10 mg/day in the last 15 days

• Patients who received rituximab previously with CD20 count of < 5 cells/microliterat the time of enrollment

• For women who are not postmenopausal (greater than or equal to [>/=] 12 months ofnon-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/oruterus): agreement to remain abstinent or use two adequate methods of contraception,including at least one method with a failure rate of less than (<) 1 percent (%) peryear, during the treatment period and for at least 18 months after the last dose ofstudy drug

• For men: agreement to remain abstinent or use two adequate methods forcontraception, including at least one method with failure rate of less than 1% peryear during the treatment period and for at least 6 months (180 days) after the lastdose of drug